3326-31-6

Usage

Uses

Used in Pharmaceutical Industry:
3',6'-Dihydroxy-6-isothiocyanatospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one is used as a pharmaceutical compound for its potential therapeutic applications. The hydroxy and isothiocyanato groups in its structure may allow for interactions with biological targets, making it a candidate for the development of new drugs.
Used in Fluorescence Polarization Binding Assays:
In the field of biochemistry and molecular biology, 3',6'-Dihydroxy-6-isothiocyanatospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one is used as a fluorescent reagent. It is particularly useful in fluorescence polarization binding assays, where it can be employed to develop inhibitors of specific protein targets, such as the inactive p38α Mitogen-activated protein kinase (MAPK). 3',6'-Dihydroxy-6-isothiocyanatospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one's fluorescence properties enable the monitoring of binding events and the assessment of compound efficacy in inhibiting the target protein.
Used in Drug Delivery Systems:
Similar to gallotannin, 3',6'-Dihydroxy-6-isothiocyanatospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one may also be utilized in the development of drug delivery systems. Its unique structure and functional groups could be exploited to improve the delivery, bioavailability, and therapeutic outcomes of various drugs, particularly in the context of cancer treatment. Organic and metallic nanoparticles could be employed as carriers for 3',6'-Dihydroxy-6-isothiocyanatospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, enhancing its potential applications in the pharmaceutical industry.

InChI:InChI=1/C21H11NO5S/c23-12-2-5-15-18(8-12)26-19-9-13(24)3-6-16(19)21(15)17-7-11(22-10-28)1-4-14(17)20(25)27-21/h1-9,23-24H

Downstream Products

• 2321-07-5 fluorescein 
• 1219601-72-5 C₃₃H₃₇N₅O₁₀S 
• 1219601-71-4 C₃₃H₃₇N₅O₁₀S 
• 1581884-54-9 C₆₆H₉₅N₃O₉S 

Relevant academic research and scientific papers

Nucleic acid size detection method

The present invention provides methods of determining the size of a particular nucleic acid segment of interest in a sample of nucleic acids through fragmentation of DNA, size fractionation, an optional second fragmentation, and identification using a marker sequence. In particular aspects, an expansion or reduction of tandem repeat sequences can be detected. In further aspects, carriers and individuals afflicted with fragile X syndrome or other diseases associated with tandem repeats can be distinguished from normal individuals.

Assay for mycobacterium avium/intracellulare nucleic acid

Disclosed is a method for determining the presence of Mycobacterium avium complex nucleic acids in a biological sample. In particular, the mig gene of M. avium and the DT1 gene of M. intracellulare are detected, preferably following amplification. In addition, the method distinguishes between species of M. avium and M. intracellulare. Also described are oligonucleotides that can be used as primers to amplify target genes such as mig and DT1 genes and as probes as well as kits containing the oligonucleotides.

PHARMACEUTICAL COMPOSITION CONTAINING STATIN-ENCAPSULATED NANOPARTICLE

The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization.

Substractive single label comparative hybridization

Provided are methods of determining differences between nucleic acids in a test sample and a reference sample. In certain embodiments the methods are used for detecting and mapping chromosomal or genetic abnormalities associated with various diseases or with predisposition to various diseases, or to detecting the phenomena of large scale copy number variants. In particular, provided are advanced methods of performing array-based comparative hybridization that allow reproducibility between samples and enhanced sensitivity by using the same detectable label for both test sample and reference sample nucleic acids. Invention methods are useful for the detection or diagnosis of particular disease conditions such as cancer, and detecting predisposition to cancer based on detection of chromosomal or genetic abnormalities and gene expression level. Invention methods are also useful for the detection or diagnosis of hereditary genetic disorders or predisposition thereto, especially in prenatal samples. Moreover, invention methods are also useful for the detection or diagnosis of de novo genetic aberrations associated with post-natal developmental abnormalities.

Activatable probes and methods for in vivo gene detection

Probes for detecting a target polynucleotide are provided. One aspect provides a molecular beacon probe set wherein the donor molecular beacon comprises a quantum dot and an acceptor molecular beacon comprises at least one reporter. The probes optionally comprise a protein transduction domain, targeting signal, or a combination thereof. Methods for detecting target polynucleotides using the disclosed probes are also provided.

Oligonucleotides comprising a molecular switch

This invention relates to oligonucleotides comprising a molecular switch which may exist in an “open” or “closed” position. The molecular switch portion of the probe is particularly sensitive to the identity of sequences complementary to the molecular switch. Oligonucleotides containing a molecular switch are applicable to all kinds of hybridization processes. Due to the sensitivity of the switch domain of the oligonucleotide, probes containing a molecular switch are particularly useful in the identification of single point mismatches. More specifically, a portion, but not all, of the oligonucleotide becomes unbound from a mismatched target. The invention further relates to methods of using said oligonucleotides for research reagents, and clinical diagnostics. An exemplary oligonucleotide comprises a first hybridizable domain, a second bridging block domain, and a third binding domain.

Dual resonance energy transfer nucleic acid probes

Dual nucleic acid probes with resonance energy transfer moieties are provided. In particular, fluorescent or luminescent resonance energy transfer moieties are provided on hairpin stem-loop molecular beacon probes that hybridize sufficiently near each other on a subject nucleic acid, e.g. mRNA, to generate an observable interaction. The invention also provides lanthanide chelate luminescent resonance energy transfer moieties on linear and stem-loop probes that hybridize sufficiently near each other on a subject nucleic acid to generate an observable interaction. The invention thereby provides detectable signals for rapid, specific and sensitive hybridization determination in vivo. The probes are used in methods of detection of nucleic acid target hybridization for the identification and quantification of tissue and cell-specific gene expression levels, including response to external stimuli, such as drug candidates, and genetic variations associated with disease, such as cancer.

Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon

The present invention provides labeled nucleic acid amplification oligonucleotides, which can be linear or hairpin primers or blocking oligonucleotides. The oligonucleotides of the invention are labeled with donor and/or acceptor moieties of molecular energy transfer pairs. The moieties can be fluorophores, such that fluorescent energy emitted by the donor is absorbed by the acceptor. The acceptor may be a fluorophore that fluoresces at a wavelength different from the donor moiety, or it may be a quencher. The oligonucleotides of the invention are configured so that a donor moiety and an acceptor moiety are incorporated into the amplification product. The invention also provides methods and kits for directly detecting amplification products employing the nucleic acid amplification primers. When labeled linear primers are used, treatment with exonuclease or by using specific temperature eliminates the need for separation of unincorporated primers. This "closed-tube" format greatly reduces the possibility of carryover contamination with amplification products, provides for high throughput of samples, and may be totally automated.

New nucleotide derivatives

Nucleotide derivatives useful in modified DNA probe synthesis are compounds having the formula (I) wherein eitherA is a radical of formula -NHCO-(CH2) x-R3 and B is a substituted pyrimidine or purine residue, orA is a hydrogen atom and B is a radical of formula (II) The terminal group R3 may comprise amino or carboxy groups, or a sugar moiety, or it may comprise a reporter group such as biotin, or luminol derivatives, or any other group which is detectable by Elisa or other means of detection. These compounds do not exist in natural DNA. The new compounds are useful as active monomers in a rapid and efficient procedure for the synthesis of DNA fragments and can be chemically incorporated in a DNA probe synthesis which allows total control over the extent and site of modification.